AI assistant
Reckitt Benckiser Group PLC — Board/Management Information 2019
Sep 18, 2019
4872_rns_2019-09-18_5bb07535-8d60-4572-bba7-d51de019034a.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7918M
Reckitt Benckiser Group PLC
18 September 2019
18 September 2019
RECKITT BENCKISER GROUP PLC
CHANGE TO NOMINATION COMMITTEE MEMBERSHIP
Reckitt Benckiser Group plc ("RB") announces that Laxman Narasimhan, Chief Executive Officer, was appointed as a member of the Board's Nomination Committee with effect from 17 September 2019.
About RB:
RB* is a leading global health, hygiene and home company inspired by a vision of the world where people are healthier and live better. Its purpose is to make a difference by giving people innovative solutions for healthier lives and happier homes.
Through its two business units, Health and Hygiene Home, RB has operations in over 60 countries and its products reach millions of people globally every day. Its trusted household brands include names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.
RB's drive to achieve, passion to outperform and commitment to quality and scientific excellence is manifested in the work of over 40,000 diverse, talented entrepreneurs worldwide.
For more information visit www.rb.com
*RB is the trading name of the Reckitt Benckiser group of companies
Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108
For further Information:
Rupert Bondy
Company Secretary
+44 (0) 1753 217 800
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BOAGGUUCBUPBURR